Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/genetic-events-other-than-bcr-abl1-zUilc1fZed
References (114)
-
A. Neubauer, M. He, C. Schmidt, D. Huhn, E. Liu (1993)
Genetic alterations in the p53 gene in the blast crisis of chronic myelogenous leukemia: analysis by polymerase chain reaction based techniques.Leukemia, 7 4
-
H. Makishima, A. Jankowska, M. McDevitt, C. O'keefe, Simon Dujardin, Heather Cazzolli, B. Przychodzen, C. Prince, J. Nicoll, H. Siddaiah, Mohammed Shaik, H. Szpurka, E. Hsi, A. Advani, R. Paquette, J. Maciejewski (2011)
CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia.Blood, 117 21
-
N. Muvarak, P. Nagaria, F. Rassool (2012)
Genomic Instability in Chronic Myeloid Leukemia: Targets for Therapy?Current Hematologic Malignancy Reports, 7
-
C. Mullighan, C. Miller, I. Radtke, Letha Phillips, J. Dalton, Jing Ma, D. White, T. Hughes, M. Beau, C. Pui, M. Relling, S. Shurtleff, J. Downing (2008)
BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of IkarosNature, 453
-
A. Fabarius, A. Leitner, A. Hochhaus, Martin Müller, B. Hanfstein, C. Haferlach, G. Göhring, B. Schlegelberger, M. Jotterand, A. Reiter, S. Jung-Munkwitz, U. Proetel, J. Schwaab, W. Hofmann, J. Schubert, H. Einsele, A. Ho, C. Falge, L. Kanz, A. Neubauer, M. Kneba, F. Stegelmann, M. Pfreundschuh, C. Waller, K. Spiekermann, G. Baerlocher, M. Lauseker, M. Pfirrmann, J. Hasford, S. Saussele, R. Hehlmann (2011)
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.Blood, 118 26
-
鈴木 圭 (2012)
IKAROS isoform 6 enhances BCR-ABL1-mediated proliferation of human CD34[+] hematopoietic cells on stromal cells -
K. Yamamoto, S. Tsuzuki, Y. Minami, Yukiya Yamamoto, A. Abe, K. Ohshima, M. Seto, T. Naoe (2013)
Functionally Deregulated AML1/RUNX1 Cooperates with BCR-ABL to Induce a Blastic Phase-Like Phenotype of Chronic Myelogenous Leukemia in MicePLoS ONE, 8
-
A. Hamilton, V. Helgason, M. Schemionek, Bin Zhang, S. Myssina, E. Allan, F. Nicolini, C. Müller-Tidow, R. Bhatia, V. Brunton, S. Koschmieder, T. Holyoake (2012)
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.Blood, 119 6
-
K. Kataoka, Tomohiko Sato, A. Yoshimi, S. Goyama, Takako Tsuruta, Hiroshi Kobayashi, M. Shimabe, S. Arai, M. Nakagawa, Y. Imai, K. Kumano, Katsuyoshi Kumagai, N. Kubota, T. Kadowaki, M. Kurokawa (2011)
Evi1 is essential for hematopoietic stem cell self-renewal, and its expression marks hematopoietic cells with long-term multilineage repopulating activityThe Journal of Experimental Medicine, 208
-
J. Savage (1976)
Classification and relationships of induced chromosomal structual changes.Journal of Medical Genetics, 13
-
K. Georgopoulos, S. Winandy, N. Avitahl (1997)
The role of the Ikaros gene in lymphocyte development and homeostasis.Annual review of immunology, 15
-
C. Jamieson, L. Ailles, S. Dylla, M. Muijtjens, Carol Jones, J. Zehnder, J. Gotlib, Kevin Li, M. Manz, A. Keating, C. Sawyers, I. Weissman (2004)
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.The New England journal of medicine, 351 7
-
(1995)
The AML 1 / Evi1 fusion protein in the t ( 3 ; 21 ) translocation exhibits transforming activity on Rat 1 fibroblasts with dependence on the Evi1 sequence -
Ye Ding, Y. Harada, J. Imagawa, A. Kimura, H. Harada (2009)
AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms.Blood, 114 25
-
Y. Ben-Neriah, G. Daley, A. Mes-Masson, O. Witte, D. Baltimore (1986)
The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene.Science, 233 4760
-
M. Figueroa, O. Abdel-Wahab, Chao Lu, P. Ward, Jay Patel, A. Shih, Yushan Li, N. Bhagwat, A. Vasanthakumar, H. Fernandez, M. Tallman, Zhuoxin Sun, K. Wolniak, J. Peeters, Wei Liu, S. Choe, V. Fantin, E. Paietta, B. Löwenberg, J. Licht, L. Godley, R. Delwel, P. Valk, C. Thompson, R. Levine, A. Melnick (2010)
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.Cancer cell, 18 6
-
J. Zhang, Z. Jin, Q.‐Y. Du, R. Li, F. Yao, B. Huang, N. Xu, L. Xu, X. Luo, X. Liu (2012)
Analysis of altered proteins related to blast crisis in chronic myeloid leukemia by proteomic studyInternational Journal of Laboratory Hematology, 34
-
Linda Scott, Peter Campbell, E. Baxter, T. Todd, P. Stephens, S. Edkins, R. Wooster, Michael Stratton, P. Futreal, Anthony Green (2005)
The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders.Blood, 106 8
-
Jia-Jie Chen, Zi-Jie Long, Dong-Fan Xu, Ruo-zhi Xiao, Ling-ling Liu, Zhifang Xu, S. Qiu, D. Lin, Quentin Liu (2014)
Inhibition of autophagy augments the anticancer activity of α-mangostin in chronic myeloid leukemia cellsLeukemia & Lymphoma, 55
-
Oshrat Rokah, G. Granot, A. Ovcharenko, S. Modai, M. Pasmanik-Chor, A. Toren, N. Shomron, O. Shpilberg (2012)
Downregulation of Mir-31, Mir-155, and Mir-564 in Chronic Myeloid Leukemia CellsPLoS ONE, 7
-
A. Weer, B. Poppe, B. Cauwelier, A. Carlier, J. Dierick, B. Verhasselt, J. Philippé, N. Roy, F. Speleman (2008)
EVI1 activation in blast crisis CML due to juxtaposition to the rare 17q22 partner region as part of a 4-way variant translocation t(9;22)BMC Cancer, 8
-
M. Notari, P. Neviani, R. Santhanam, B. Blaser, J. Chang, A. Galietta, A. Willis, D. Roy, M. Caligiuri, G. Marcucci, D. Perrotti (2006)
A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation.Blood, 107 6
-
Jing Yang, T. Ikezoe, C. Nishioka, K. Udaka, A. Yokoyama (2014)
Bcr‐Abl activates AURKA and AURKB in chronic myeloid leukemia cells via AKT signalingInternational Journal of Cancer, 134
-
E. Nacheva, D. Brazma, A. Virgili, Julie Howard‐Reeves, A. Chanalaris, K. Gancheva, M. Apostolova, M. Valgañón, H. Mazzullo, C. Grace (2010)
Deletions of Immunoglobulin heavy chain and T cell receptor gene regions are uniquely associated with lymphoid blast transformation of chronic myeloid leukemiaBMC Genomics, 11
-
D. Goff, Angela Recart, A. Sadarangani, Hye-Jung Chun, Christian Barrett, M. Krajewska, Heather Leu, Janine Low-Marchelli, Wenxue Ma, Alice Shih, Jun Wei, D. Zhai, I. Geron, Minya Pu, L. Bao, R. Chuang, L. Balaian, J. Gotlib, M. Minden, G. Martinelli, Jessica Rusert, K. Dao, K. Shazand, P. Wentworth, Kristen Smith, C. Jamieson, S. Morris, Karen Messer, L. Goldstein, T. Hudson, M. Marra, K. Frazer, M. Pellecchia, John Reed, C. Jamieson (2013)
A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition.Cell stem cell, 12 3
-
T. Nakajima, M. Moriguchi, Y. Mitsumoto, S. Sekoguchi, Taichirou Nishikawa, Hidetaka Takashima, Tadashi Watanabe, Tatsuo Katagishi, H. Kimura, T. Okanoue, K. Kagawa (2004)
Centrosome aberration accompanied with p53 mutation can induce genetic instability in hepatocellular carcinomaModern Pathology, 17
-
O. Abdel-Wahab, Mazhar Adli, Lindsay LaFave, Jie Gao, Todd Hricik, A. Shih, Suveg Pandey, Jay Patel, Y. Chung, R. Koche, F. Perna, Xinyang Zhao, Jordan Taylor, Christopher Park, M. Carroll, A. Melnick, S. Nimer, Jacob Jaffe, I. Aifantis, B. Bernstein, R. Levine (2012)
ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.Cancer cell, 22 2
-
Y. Minami, S. Stuart, T. Ikawa, Yong-chao Jiang, A. Banno, I. Hunton, D. Young, T. Naoe, C. Murre, C. Jamieson, Jean Wang (2008)
BCR-ABL-transformed GMP as myeloid leukemic stem cellsProceedings of the National Academy of Sciences, 105
-
K. Kuželová, Z. Hrkal (2008)
Rho-signaling pathways in chronic myelogenous leukemia.Cardiovascular & hematological disorders drug targets, 8 4
-
M. Deininger, J. Goldman, J. Melo (2000)
The molecular biology of chronic myeloid leukemia.Blood, 96 10
-
E. Jabbour, J. Lipton (2013)
A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase.Clinical lymphoma, myeloma & leukemia, 13 6
-
Sujiang Zhang, Jing-yi Shi, Jian-yong Li (2009)
GATA-2 L359 V mutation is exclusively associated with CML progression but not other hematological malignancies and GATA-2 P250A is a novel single nucleotide polymorphism.Leukemia research, 33 8
-
CC Yin, J Cortes, B Barkoh, K Hayes, H Kantarjian, D Jones (2006)
t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapyCancer, 106
-
A. Quintás-Cardama, Y. Qiu, S. Post, Yiqun Zhang, C. Creighton, J. Cortes, S. Kornblau (2012)
Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34‐positive compartmentCancer, 118
-
G. Reddiconto, C. Toto, I. Palamà, S. Leo, Emanuela Luca, S. Matteis, L. Dini, C. Passerini, N. Renzo, M. Maffia, A. Coluccia (2012)
Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.Blood, 119 10
-
Sreenath Sharma, J. Settleman (2007)
Oncogene addiction: setting the stage for molecularly targeted cancer therapy.Genes & development, 21 24
-
K. Mitani, S. Ogawa, Tomoyuki Tanaka, H. Miyoshi, M. Kurokawa, H. Mano, Y. Yazaki, M. Ohki, H. Hirai (1994)
Generation of the AML1‐EVI‐1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia.The EMBO Journal, 13
-
Zaen-Al-Abideen Pahore, T. Shamsi, M. Taj, T. Farzana, S. Ansari, M. Nadeem, Masood Ahmad, A. Naz (2011)
JAK2V617F mutation in chronic myeloid leukemia predicts early disease progression.Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 21 8
-
G. Nucifora (1997)
The EVI1 gene in myeloid leukemiaLeukemia, 11
-
Jason Harb, P. Neviani, B. Chyla, Justin Ellis, Gregory Ferenchak, J. Oaks, Christopher Walker, Peter Hokland, Denis-Claude Roy, M. Caligiuri, G. Marcucci, C. Huettner, C. Huettner, D. Perrotti (2013)
Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic targetLeukemia, 27
-
T. Stokłosa, E. Głodkowska-Mrówka, G. Hoser, Magdalena Kielak, I. Seferyńska, P. Włodarski (2013)
Diverse mechanisms of mTOR activation in chronic and blastic phase of chronic myelogenous leukemia.Experimental hematology, 41 5
-
Xiaoyan Jiang, Kyi Saw, A. Eaves, C. Eaves (2007)
Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.Journal of the National Cancer Institute, 99 9
-
M. Brecqueville, J. Rey, F. Bertucci, E. Coppin, P. Finetti, N. Carbuccia, N. Cervera, V. Gelsi-Boyer, C. Arnoulet, O. Gisserot, D. Verrot, B. Slama, N. Vey, M. Mozziconacci, D. Birnbaum, A. Murati (2012)
Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasmsGenes, 51
-
F. Giles, J. Cortes, Dan Jones, D. Bergstrom, H. Kantarjian, S. Freedman (2007)
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation.Blood, 109 2
-
V. Morris, Ailin Zhang, Taimei Yang, Derek Stirewalt, Ranjani Ramamurthy, S. Meshinchi, V. Oehler (2013)
MicroRNA-150 Expression Induces Myeloid Differentiation of Human Acute Leukemia Cells and Normal Hematopoietic ProgenitorsPLoS ONE, 8
-
W. Zhao, H. He, K. Ren, B. Li, H. Zhang, Y. Lin, R. Shao (2013)
MR-1 blocks the megakaryocytic differentiation and transition of CML from chronic phase to blast crisis through MEK dephosphorylationBlood Cancer Journal, 3
-
W. Al-achkar, Abdulmunim Aljapawe, Suher Almedani, T. Liehr, A. Wafa (2012)
A novel cytogenetic abnormality t(7;8)(p11.2:q11.2) and a four-way Philadelphia translocation in an imatinib mesylate-resistant chronic myeloid leukemia patientOncology Letters, 5
-
Yuxia Yang, Saifeng Wang, Yanju Zhang, Xiaoling Zhu (2012)
Biological effects of decreasing RBM15 on chronic myelogenous leukemia cellsLeukemia & Lymphoma, 53
-
(1994)
Generation of the AML 1 - EVI1 fusion gene in the t ( 3 ; 21 ) ( q 26 ; q 22 ) causes blastic crisis in chronic myelocytic leuke -
(2013)
Protein phosphatase 2 A : a target for anti - cancer therapy -
C. Meyer, B. Schneider, S. Jakob, S. Strehl, A. Attarbaschi, Susanne Schnittger, C. Schoch, M. Jansen, J. Dongen, M. Boer, R. Pieters, M. Ennas, E. Angelucci, U. Koehl, J. Greil, F. Griesinger, U. Stadt, C. Eckert, T. Szczepański, F. Niggli, B. Schäfer, H. Kempski, H. Brady, J. Zuna, J. Trka, L. Nigro, A. Biondi, É. Delabesse, E. Macintyre, M. Stanulla, M. Schrappe, O. Haas, T. Burmeister, T. Dingermann, T. Klingebiel, R. Marschalek (2006)
The MLL recombinome of acute leukemiasLeukemia, 20
-
M. Giehl, A. Fabarius, O. Frank, A. Hochhaus, M. Hafner, Ruediger Hehlmann, W. Seifarth (2005)
Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instabilityLeukemia, 19
-
M. Nieborowska-Skorska, P. Kopinski, R. Ray, G. Hoser, Danielle Ngaba, S. Flis, Kimberly Cramer, M. Reddy, Mateusz Koptyra, Tyrone Penserga, E. Głodkowska-Mrówka, E. Bolton, T. Holyoake, C. Eaves, S. Cerny‐Reiterer, P. Valent, A. Hochhaus, T. Hughes, Heiko Kuip, M. Sattler, W. Wiktor-Jedrzejczak, C. Richardson, A. Dorrance, T. Stokłosa, David Williams, T. Skorski (2012)
Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors.Blood, 119 18
-
J. Rowley (1973)
A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa StainingNature, 243
-
R. Paquette, J. Nicoll, Meenal Chalukya, D. Elashoff, N. Shah, C. Sawyers, E. Spiteri, G. Nanjangud, P. Rao (2011)
Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors.Cancer genetics, 204 7
-
P. Neviani, Jason Harb, J. Oaks, R. Santhanam, C. Walker, Justin Ellis, Gregory Ferenchak, A. Dorrance, Carolyn Paisie, A. Eiring, Yihui Ma, H. Mao, Bin Zhang, M. Wunderlich, P. May, Chaode Sun, S. Saddoughi, J. Bielawski, W. Blum, R. Klisovic, Janelle Solt, J. Byrd, S. Volinia, J. Cortes, C. Huettner, S. Koschmieder, T. Holyoake, S. Devine, M. Caligiuri, C. Croce, R. Garzon, B. Ogretmen, R. Arlinghaus, Ching Chen, R. Bittman, P. Hokland, D. Roy, D. Milojkovic, J. Apperley, J. Goldman, A. Reid, J. Mulloy, R. Bhatia, G. Marcucci, D. Perrotti (2013)
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.The Journal of clinical investigation, 123 10
-
Kelly Moran-Crusio, Linsey Reavie, A. Shih, O. Abdel-Wahab, Delphine Ndiaye-Lobry, C. Lobry, M. Figueroa, A. Vasanthakumar, Jay Patel, Xinyang Zhao, F. Perna, Suveg Pandey, J. Madzo, Chun-Xiao Song, Qing Dai, Chuan He, S. Ibrahim, M. Beran, J. Zavadil, S. Nimer, A. Melnick, L. Godley, I. Aifantis, R. Levine (2011)
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.Cancer cell, 20 1
-
C. Meyer, J. Hofmann, T. Burmeister, D. Gröger, T. Park, M. Emerenciano, M. Oliveira, Aline Renneville, P. Villarese, E. Macintyre, H. Cavé, E. Clappier, K. Mass-Malo, J. Zuna, J. Trka, E. Braekeleer, M. Braekeleer, S. Oh, G. Tsaur, L. Fechina, V. Velden, J. Dongen, É. Delabesse, R. Binato, M. Silva, A. Kustanovich, O. Aleinikova, M. Harris, T. Lund-Aho, V. Juvonen, O. Heidenreich, J. Vormoor, W. Choi, M. Jarošová, A. Kolenová, C. Bueno, P. Menéndez, S. Wehner, C. Eckert, P. Talmant, S. Tondeur, E. Lippert, E. Launay, C. Henry, P. Ballerini, H. Lapillone, M. Callanan, J. Cayuela, C. Herbaux, G. Cazzaniga, P. Kakadiya, S. Bohlander, M. Ahlmann, J. Choi, P. Gameiro, D. Lee, J. Krauter, P. Cornillet‐Lefèbvre, G. Kronnie, B. Schäfer, S. Kubetzko, C. Alonso, U. Stadt, R. Sutton, N. Venn, S. Izraeli, L. Trakhtenbrot, H. Madsen, P. Archer, J. Hancock, N. Cerveira, M. Teixeira, L. Nigro, A. Möricke, M. Stanulla, M. Schrappe, L. Sędek, T. Szczepański, C. Zwaan, E. Coenen, M. Heuvel-Eibrink, S. Strehl, M. Dworzak, R. Panzer-Grümayer, T. Dingermann, T. Klingebiel, R. Marschalek (2013)
The MLL recombinome of acute leukemias in 2013Leukemia, 27
-
V. Grossmann, A. Kohlmann, M. Zenger, S. Schindela, C. Eder, S. Weissmann, S. Schnittger, W. Kern, M. Müller, A. Hochhaus, T. Haferlach, C. Haferlach (2011)
A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of casesLeukemia, 25
-
C. Yin, J. Cortes, B. Barkoh, K. Hayes, H. Kantarjian, Dan Jones (2006)
t(3;21)(q26;q22) in myeloid leukemiaCancer, 106
-
R. Piazza, S. Valletta, N. Winkelmann, S. Redaelli, R. Spinelli, A. Pirola, L. Antolini, L. Mologni, C. Donadoni, E. Papaemmanuil, S. Schnittger, Dong-Wook Kim, J. Boultwood, F. Rossi, G. Gaipa, G. Martini, P. Celle, H. Jang, V. Fantin, G. Bignell, V. Magistroni, T. Haferlach, E. Pogliani, P. Campbell, A. Chase, W. Tapper, N. Cross, C. Gambacorti-Passerini (2012)
Recurrent SETBP1 mutations in atypical chronic myeloid leukemiaNature Genetics, 45
-
F. Oliveira, Leonardo Palma, R. Falcão, B. Simões (2012)
A new dic(7;12)(p12.21;p12.2) and i(12)(q10) during the lymphoid blast crisis of patient with Ph+ chronic myeloid leukemiaMedical Oncology, 29
-
(2013)
Transcriptional suppression of BACH 2 by the Bcr - Abl oncoprotein is mediated by PAX 5 -
W. Al-achkar, A. Wafa, Suher Almedani (2010)
BCR translocation to derivative chromosome 2: a new case of chronic myeloid leukemia with a complex variant translocation and Philadelphia chromosome.Oncology letters, 1 3
-
Centrosome aberrations in chronic myeloid -
C. Mullighan, R. Williams, J. Downing, C. Sherr (2008)
Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL.Genes & development, 22 11
-
J. Cofre, J. Menezes, L. Pizzatti, E. Abdelhay (2012)
Knock-down of Kaiso induces proliferation and blocks granulocytic differentiation in blast crisis of chronic myeloid leukemiaCancer Cell International, 12
-
A. Eiring, Jason Harb, P. Neviani, C. Garton, J. Oaks, R. Spizzo, Shujun Liu, S. Schwind, R. Santhanam, Christopher Hickey, H. Becker, J. Chandler, R. Andino, J. Cortes, P. Hokland, C. Huettner, R. Bhatia, D. Roy, S. Liebhaber, M. Caligiuri, G. Marcucci, R. Garzon, C. Croce, G. Calin, D. Perrotti (2010)
miR-328 Functions as an RNA Decoy to Modulate hnRNP E2 Regulation of mRNA Translation in Leukemic BlastsCell, 140
-
R. Hehlmann (2012)
How I treat CML blast crisis.Blood, 120 4
-
R. Hehlmann, M. Lauseker, S. Jung-Munkwitz, A. Leitner, Martin Müller, Nadine Pletsch, U. Proetel, C. Haferlach, B. Schlegelberger, L. Balleisen, M. Hänel, M. Pfirrmann, S. Krause, C. Nerl, H. Pralle, A. Gratwohl, D. Hossfeld, J. Hasford, A. Hochhaus, S. Saussele (2011)
Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 12
-
Zainab Jagani, Keli Song, J. Kutok, M. Dewar, Armelle Melet, T. Santos, A. Grassian, S. Ghaffari, Catherine Wu, H. Yeckes-Rodin, R. Ren, Kenneth Miller, R. Khosravi‐Far (2009)
Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors.Cancer research, 69 16
-
(2009)
nase inhibitor-induced cell death in Philadelphia chromosomepositive cells, including primary CML stem cells -
U Thorsteinsdottir, A Mamo, E Kroon, L Jerome, J Bijl, HJ Lawrence (2002)
Overexpression of the myeloid leukemia-associated Hoxa9 gene in bone marrow cells induces stem cell expansionBlood, 99
-
W. Haass, Michael Stehle, S. Nittka, M. Giehl, P. Schrotz-King, A. Fabarius, W. Hofmann, W. Seifarth (2012)
The Proteolytic Activity of Separase in BCR-ABL-Positive Cells Is Increased by ImatinibPLoS ONE, 7
-
D. Perrotti, C. Jamieson, J. Goldman, T. Skorski (2010)
Chronic myeloid leukemia: mechanisms of blastic transformation.The Journal of clinical investigation, 120 7
-
H. Patel, M. Gordon (2009)
Abnormal centrosome‐centriole cycle in chronic myeloid leukaemia?British Journal of Haematology, 146
-
WenYong Chen, R. Bhatia (2013)
Roles of SIRT1 in leukemogenesisCurrent Opinion in Hematology, 20
-
Seung-Tae Lee, Yongick Ji, Hee-Jin Kim, C. Ki, C. Jung, Jong-Won Kim, Sun-Hee Kim (2012)
Sequential array comparative genomic hybridization analysis identifies copy number changes during blastic transformation of chronic myeloid leukemia.Leukemia research, 36 4
-
(2013)
alpha-mangostin in chronic myeloid leukemia cells -
L. Crews, C. Jamieson (2013)
Selective elimination of leukemia stem cells: hitting a moving target.Cancer letters, 338 1
-
Ling Li, Lisheng Wang, Liang Li, Zhiqiang Wang, Yinwei Ho, Tinisha McDonald, T. Holyoake, WenYong Chen, R. Bhatia (2012)
Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib.Cancer cell, 21 2
-
B. Calabretta, D. Perrotti (2004)
The biology of CML blast crisis.Blood, 103 11
-
C. Roche-Lestienne, Lauréline Deluche, S. Corm, I. Tigaud, S. Joha, N. Philippe, S. Geffroy, J. Laï, F. Nicolini, C. Preudhomme (2007)
RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.Blood, 111 7
-
C. Bellodi, M. Lidonnici, A. Hamilton, G. Helgason, A. Soliera, M. Ronchetti, S. Galavotti, K. Young, Tommaso Selmi, R. Yacobi, R. Etten, N. Donato, A. Hunter, D. Dinsdale, E. Tirrò, P. Vigneri, P. Nicotera, M. Dyer, T. Holyoake, P. Salomoni, K. Funai, Haowei Song, L. Yin, I. Lodhi, Xiaochao Wei, J. Yoshino, T. Coleman, C. Semenkovich, Aldo Roccaro, A. Sacco, P. Maiso, A. Azab, Y. Tai, M. Reagan, F. Azab, L. Flores, F. Campigotto, E. Weller, K. Anderson, D. Scadden, I. Ghobrial, S. Ramachandrappa, Anne Raimondo, A. Calí, J. Keogh, E. Henning, Sadia Saeed, A. Thompson, Sumedha Garg, Elena Bochukova, S. Brage, Victoria Trowse, E. Wheeler, Adrienne Sullivan, M. Dattani, Peter Clayton, V. Datta, J. Bruning, N. Wareham, S. O’Rahilly, D. Peet, I. Barroso, M. Whitelaw, S. Farooqi (2009)
Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.The Journal of clinical investigation, 119 5
-
L. Laricchia‐Robbio, K. Premanand, C. Rinaldi, G. Nucifora (2009)
EVI1 Impairs myelopoiesis by deregulation of PU.1 function.Cancer research, 69 4
-
M. Kurokawa, Seishi Ogawa, Tomoyuki Tanaka, K. Mitani, Yoshio Yazaki, Owen Witte, Hisamaru Hirai (1995)
The AML1/Evi-1 fusion protein in the t(3;21) translocation exhibits transforming activity on Rat1 fibroblasts with dependence on the Evi-1 sequence.Oncogene, 11 5
-
F. Mitelman, G. Levan, P. Nilsson, L. Brandt (1976)
Non‐random karyotypic evolution in chronic myeloid leukemiaInternational Journal of Cancer, 18
-
Christos Tsatsanis, D. Spandidos (2000)
The role of oncogenic kinases in human cancer (Review).International journal of molecular medicine, 5 6
-
O. Abdel-Wahab, T. Manshouri, Jay Patel, K. Harris, Jinjuan Yao, C. Hedvat, A. Heguy, C. Bueso-Ramos, H. Kantarjian, R. Levine, S. Verstovsek (2010)
Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.Cancer research, 70 2
-
H. Nakayama, F. Ishimaru, N. Avitahl, N. Sezaki, N. Fujii, K. Nakase, Y. Ninomiya, A. Harashima, J. Minowada, J. Tsuchiyama, K. Imajoh, T. Tsubota, S. Fukuda, T. Sezaki, K. Kojima, M. Hara, H. Takimoto, S. Yorimitsu, Isao Takahashi, A. Miyata, S. Taniguchi, Y. Tokunaga, H. Gondo, Y. Niho, S. Nakao, T. Kyo, H. Dohy, N. Kamada, M. Harada (1999)
Decreases in Ikaros activity correlate with blast crisis in patients with chronic myelogenous leukemia.Cancer research, 59 16
-
R. Levine, M. Loriaux, B. Huntly, M. Loh, M. Beran, E. Stoffregen, R. Berger, Jennifer Clark, S. Willis, Kim Nguyen, N. Flores, E. Estey, N. Gattermann, S. Armstrong, A. Look, J. Griffin, O. Bernard, M. Heinrich, D. Gilliland, B. Druker, M. Deininger (2005)
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.Blood, 106 10
-
R. Williams, C. Sherr (2008)
The INK4-ARF (CDKN2A/B) locus in hematopoiesis and BCR-ABL-induced leukemias.Cold Spring Harbor symposia on quantitative biology, 73
-
K. Shimada, A. Tomita, Y. Minami, A. Abe, C. Hind, H. Kiyoi, M. Cragg, T. Naoe (2012)
CML cells expressing the TEL/MDS1/EVI1 fusion are resistant to imatinib-induced apoptosis through inhibition of BAD, but are resensitized with ABT-737.Experimental hematology, 40 9
-
J. Welch, T. Ley, D. Link, Christopher Miller, D. Larson, D. Koboldt, L. Wartman, T. Lamprecht, Fulu Liu, Jun Xia, C. Kandoth, R. Fulton, M. McLellan, D. Dooling, J. Wallis, Ken Chen, C. Harris, Heather Schmidt, Joelle Kalicki-Veizer, Charles Lu, Qunyuan Zhang, Ling Lin, M. O'Laughlin, Joshua McMichael, K. Delehaunty, L. Fulton, V. Magrini, S. McGrath, Ryan Demeter, T. Vickery, J. Hundal, L. Cook, Gary Swift, Jerry Reed, Patricia Alldredge, T. Wylie, Jason Walker, M. Watson, S. Heath, W. Shannon, Nobish Varghese, R. Nagarajan, J. Payton, J. Baty, S. Kulkarni, J. Klco, M. Tomasson, P. Westervelt, M. Walter, T. Graubert, J. Dipersio, L. Ding, E. Mardis, R. Wilson (2012)
The Origin and Evolution of Mutations in Acute Myeloid LeukemiaCell, 150
-
Li-Juan Zhao, Yue-Ying Wang, Guo Li, Li-yuan Ma, S. Xiong, Xiang-Qin Weng, Wei-na Zhang, Bo Wu, Zhu Chen, Saijuan Chen (2012)
Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia.Blood, 119 12
-
F. Iovino, L. Lentini, A. Amato, A. Leonardo (2006)
RB acute loss induces centrosome amplification and aneuploidy in murine primary fibroblastsMolecular Cancer, 5
-
A. Corbin, A. Agarwal, M. Loriaux, J. Cortes, M. Deininger, B. Druker (2011)
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.The Journal of clinical investigation, 121 1
-
C. Sherr (2004)
Principles of Tumor SuppressionCell, 116
-
S. Annamaneni, Sailaja Kagita, M. Gorre, R. Digumarti, Vishnupriya Satti, Mohan Battini (2014)
Methylation status of CEBPA gene promoter in chronic myeloid leukemiaHematology, 19
-
R. Toydemir, L. Rowe, M. Hibbard, M. Salama, S. Shetty (2010)
Cytogenetic and molecular characterization of double inversion 3 associated with a cryptic BCR-ABL1 rearrangement and additional genetic changes.Cancer genetics and cytogenetics, 201 2
-
Spiers As (1977)
The clinical features of chronic granulocytic leukaemia. -
F. Albano, L. Anelli, A. Zagaria, N. Coccaro, A. Minervini, A. Rossi, G. Specchia (2011)
Decreased TET2 gene expression during chronic myeloid leukemia progression.Leukemia research, 35 11
-
D. Casolari, M. Makri, C. Yoshida, A. Muto, K. Igarashi, J. Melo (2013)
Transcriptional suppression of BACH2 by the Bcr-Abl oncoprotein is mediated by PAX5Leukemia, 27
-
H. Makishima, A. Jankowska, M. McDevitt, Simon Dujardin, Heather Cazzolli, B. Przychodzen, C. Prince, J. Nicoll, S. Harish, Mohammed Shaik, E. Hsi, A. Advani, R. Paquette, J. Maciejewski (2010)
CBL, CBLB, TET2, ASXL1, and IDH1/2 Mutations as Well as Additional Chromosomal Aberrations Constitute Molecular Events Contributing to Malignant Progression In Advanced Philadelphia Chromosome-Positive Disorders.Blood, 116
-
F. Pellicanò, A. Sinclair, T. Holyoake (2011)
In Search of CML Stem Cells’ Deadly WeaknessCurrent Hematologic Malignancy Reports, 6
-
A. Lamontanara, E. Gencer, O. Kuzyk, O. Hantschel (2013)
Mechanisms of resistance to BCR-ABL and other kinase inhibitors.Biochimica et biophysica acta, 1834 7
-
W. Warsch, C. Walz, V. Sexl (2013)
JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia.Blood, 122 13
-
Elisabeth Bolton-Gillespie, M. Schemionek, H. Klein, S. Flis, G. Hoser, T. Lange, M. Nieborowska-Skorska, J. Maier, Linda Kerstiens, Mateusz Koptyra, Martin Müller, Hardik Modi, T. Stokłosa, I. Seferyńska, R. Bhatia, T. Holyoake, S. Koschmieder, T. Skorski (2013)
Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells.Blood, 121 20
-
D. Perrotti, P. Neviani (2013)
Protein phosphatase 2A: a target for anticancer therapy.The Lancet. Oncology, 14 6
-
Sujiang Zhang, Li-yuan Ma, Qiuhua Huang, Guo Li, B. Gu, Xiao-dong Gao, Jing-yi Shi, Yue-Ying Wang, Li Gao, Xun Cai, R. Ren, Jiang Zhu, Zhu Chen, Saijuan Chen (2008)
Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemiaProceedings of the National Academy of Sciences, 105
-
U. Thorsteinsdóttir, A. Mamo, Evert Kroon, Lori Jerome, J. Bijl, H. Lawrence, K. Humphries (2001)
marrow cells induces stem cell expansion gene in bone Hoxa 9 associated − Overexpression of the myeloid leukemia -
E. Jabbour, S. Parikh, H. Kantarjian, J. Cortes (2011)
Chronic myeloid leukemia: mechanisms of resistance and treatment.Hematology/oncology clinics of North America, 25 5
-
Ross Kinstrie, M. Copland (2013)
Targeting Chronic Myeloid Leukemia Stem CellsCurrent Hematologic Malignancy Reports, 8
-
S. Soverini, A. Hochhaus, F. Nicolini, F. Gruber, T. Lange, G. Saglio, F. Pane, Martin Müller, T. Ernst, G. Rosti, K. Porkka, M. Baccarani, N. Cross, G. Martinelli (2011)
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.Blood, 118 5
- Publisher
- Springer Journals
- Copyright
- Copyright © 2014 by Springer Science+Business Media New York
- Subject
- Medicine & Public Health; Hematology; Oncology; Geriatrics/Gerontology
- ISSN
- 1558-8211
- eISSN
- 1558-822X
- DOI
- 10.1007/s11899-013-0194-x
- pmid
- 24407376
- Publisher site
- See Article on Publisher Site
Abstract
The BCR-ABL1 oncoprotein is the cause of chronic myeloid leukemia and occurs as a consequence of the translocation t(9;22), a well-defined genetic event that results in the formation of the Philadelphia chromosome. While this genomic aberration is recognized to be the main culprit of the chronic phase of chronic myeloid leukemia, the natural clonal evolution of this myeloproliferative neoplasm involves the accumulation of secondary alterations through genomic instability. Thus, efforts to dissect the frequency and nature of the genomic events at diagnosis and at later stages are producing valuable insights into understanding the mechanisms of blastic transformation and development of resistance in chronic myeloid leukemia. The identification of alternative BCR-ABL1-dependent and BCR-ABL1-independent targets that sustain the survival of leukemic blasts and/or leukemia-initiating cells will facilitate the development of novel viable therapeutic options for patients who become resistant or intolerant to the currently available therapeutic options based on tyrosine kinase inhibitors.
Journal
Current Hematologic Malignancy Reports – Springer Journals
Published: Jan 10, 2014